Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
04 Novembre 2024 - 4:00PM
Business Wire
Pfizer Inc. (NYSE: PFE) invites investors and the general public
to view and listen to a webcast of a discussion with Aamir Malik,
Chief U.S. Commercial Officer, Executive Vice President, at the UBS
Global Healthcare Conference on Wednesday, November 13, 2024 at
12:30 p.m. PST.
To view and listen to the webcast, visit our web site at
www.pfizer.com/investors. Information on accessing and registering
for the webcast will be available at www.pfizer.com/investors
beginning today.
The transcript and webcast replay of the discussion will be made
available on our web site at www.pfizer.com/investors within 24
hours after the end of the live discussion and will be accessible
for at least 90 days.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
175 years, we have worked to make a difference for all who rely on
us. We routinely post information that may be important to
investors on our website at www.Pfizer.com. In addition, to learn
more, please visit us on www.Pfizer.com and follow us on X at
@Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook
at Facebook.com/Pfizer.
Disclosure Notice: The webcast may include
forward-looking statements about, among other things, expectations
for our product pipeline, in-line products and product candidates,
including anticipated regulatory submissions, data read-outs, study
starts, approvals, launches, clinical trial results and other
developing data, revenue contribution and projections, potential
pricing and reimbursement, potential market dynamics, size and
utilization rates, growth, performance, timing of exclusivity and
potential benefits; our anticipated operating and financial
performance, including financial guidance and projections;
reorganizations, business plans, strategy and prospects; strategic
reviews; capital allocation objectives; plans for and prospects of
our acquisitions, dispositions and other business development
activities, and our ability to successfully capitalize on these
opportunities; manufacturing and product supply; our efforts to
respond to COVID-19, including our COVID-19 products our
expectations regarding the impact of COVID-19 on our business,
operations and financial results; and other statements about our
business, operations and financial results, that are subject to
substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such
statements. A description of these risks and uncertainties can be
found in Pfizer’s Annual Report on Form 10-K for the fiscal year
ended December 31, 2023 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
The forward-looking statements in the webcast speak only as of
the original date of the webcast. Pfizer assumes no obligation to
update forward-looking statements contained in the webcast as the
result of new information or future events or developments.
Category: Finance
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241104843429/en/
Media Contact: PfizerMediaRelations@Pfizer.com +1 (212) 733-1226
Investor Contact: IR@Pfizer.com +1 (212) 733-4848
Grafico Azioni Pfizer (NYSE:PFE)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Pfizer (NYSE:PFE)
Storico
Da Nov 2023 a Nov 2024